Načítá se...
Targeting molecular resistance in castration-resistant prostate cancer
Multiple mechanisms of resistance contribute to the inevitable progression of hormone-sensitive prostate cancer to castration-resistant prostate cancer (CRPC). Currently approved therapies for CRPC include systemic chemotherapy (docetaxel and cabazitaxel) and agents targeting the resistance pathways...
Uloženo v:
| Vydáno v: | BMC Med |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
BioMed Central
2015
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4556222/ https://ncbi.nlm.nih.gov/pubmed/26329698 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12916-015-0457-6 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|